ArticleNature reviews. Drug discovery2010
Roflumilast.
Article in Nature reviews. Drug discovery, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Chemical, Biochemical, and Structural Similarities and Differences of Dermatological cAMP Phosphodiesterase-IV Inhibitors.The Journal of investigative dermatology · 2025Article
- A real-world disproportionality analysis of roflumilast using the US food and drug administration adverse event reporting system data.Frontiers in drug safety and regulation · 2025Article
- Pre-Clinical Assessment of Roflumilast Therapy in a Thoracic Model of Spinal Cord Injury.Pharmaceutics · 2023Article
- Ligustrazine Inhibits Lung Phosphodiesterase Activity in a Rat Model of Allergic Asthma.Computational and mathematical methods in medicine · 2022Article
- Scope of adjuvant therapy using roflumilast, a PDE-4 inhibitor against COVID-19.Pulmonary pharmacology & therapeutics · 2021Review
- Roflumilast reverses polymicrobial sepsis-induced liver damage by inhibiting inflammation in mice.Laboratory investigation; a journal of technical methods and pathology · 2017Article
- Psiguajadials A-K: Unusual Psidium Meroterpenoids as Phosphodiesterase-4 Inhibitors from the Leaves of Psidium guajava.Scientific reports · 2017Article
- Inhibition of type 4 cyclic nucleotide phosphodiesterase blocks intracellular TLR signaling in chronic lymphocytic leukemia and normal hematopoietic cells.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases.Dermatology and therapy · 2013Article
- Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4).Biochemical pharmacology · 2013Article
- Clinical highlights from the 2011 ERS Congress in Amsterdam.The European respiratory journal · 2012Article
- Use of a soluble epoxide hydrolase inhibitor in smoke-induced chronic obstructive pulmonary disease.American journal of respiratory cell and molecular biology · 2012Article
- LPS-induced lung inflammation in marmoset monkeys - an acute model for anti-inflammatory drug testing.PloS one · 2012Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
20885403What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.